If you have been reading about DAC linker and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
=== 2017: Two Masters titles, world No. 3 === During the 2017 season, Zverev greatly improved his results at the higher level tournaments on the ATP Tour except for the four major events. It was at this time Zverev, who had been using his nickname Sascha, stated in a postmatch interview with Pam Shriver, that he would no longer be referred to as Sascha. Zverev stated that only his close family can refer to him as Sascha, as he was born in Germany and identifies as a German, and does not want a Russian nickname to be used for his professional career. At the Australian Open, Zverev again pushed Rafael Nadal to the brink, but ultimately lost in five sets. His next ATP tournament was the Open Sud de France, where he won both the singles and doubles events. He and his brother defeated Fabrice Martin and Daniel Nestor for Alexander's first doubles title. The following month, he made his first Masters quarterfinal at the Miami Open, upsetting No. 3 Stan Wawrinka along the way. Nick Kyrgios defeated him at both Masters events that month. After a slow start to the clay court season, Zverev won two more titles in May, the first of which came at home in Germany at the Bavarian International Tennis Championships. He then followed up a second Masters quarterfinal at the Madrid Open with his first Masters title at the Rome Masters. He defeated Novak Djokovic in the final to become the youngest Masters champion since Djokovic in 2007 and the first such champion born in the 1990s. With the title, he also entered the top 10 for the first time.
The nobility, which had obtained legal ownership of vast expanses of land on the Dnipro from the Polish kings, attempted to impose feudal dependency on the local population. Landowners utilized the locals in war, by raising the Cossack registry in times of hostility, and then radically decreasing it and forcing the Cossacks back into serfdom in times of peace. This institutionalized method of control bred discontent among the Cossacks. By the end of the 16th century, they began to revolt, in the uprisings of Kryshtof Kosynsky (1591–1593), Severyn Nalyvaiko (1594–1596), Hryhorii Loboda (1596), Marko Zhmailo (1625), Taras Fedorovych (1630), Ivan Sulyma (1635), Pavlo Pavliuk and Dmytro Hunia (1637), and Yakiv Ostrianyn and Karpo Skydan (1638). All were brutally suppressed and ended by the Polish government. Cossack rebellions eventually culminated in the Khmelnytsky Uprising, led by the hetman of the Zaporizhian Sich, Bohdan Khmelnytsky.
Also, adulteration of some herbal medicine preparations with conventional drugs which may cause serious adverse effects, such as corticosteroids, phenylbutazone, phenytoin, and glibenclamide, has been reported. Substances known to be potentially dangerous include Aconitum, secretions from the Asiatic toad, powdered centipede, the Chinese beetle (Mylabris phalerata), certain fungi, Aristolochia (which is known to cause cancer). arsenic sulfide (realgar), mercury sulfide, and cinnabar. Asbestos ore (Actinolite, Yang Qi Shi, 阳起石) is used to treat impotence in TCM. Due to galena's (litharge, lead(II) oxide) high lead content, it is known to be toxic. Lead, mercury, arsenic, copper, cadmium, and thallium have been detected in TCM products sold in the U.S. and China. To avoid its toxic adverse effects Xanthium sibiricum must be processed. Hepatotoxicity has been reported with products containing Reynoutria multiflora (synonym Polygonum multiflorum), glycyrrhizin, Senecio and Symphytum. The herbs indicated as being hepatotoxic included Dictamnus dasycarpus, Astragalus membranaceus, and Paeonia lactiflora. Contrary to popular belief, Ganoderma lucidum mushroom extract, as an adjuvant for cancer immunotherapy, appears to have the potential for toxicity. A 2013 review suggested that although the antimalarial herb Artemisia annua may not cause hepatotoxicity, haematotoxicity, or hyperlipidemia, it should be used cautiously during pregnancy due to a potential risk of embryotoxicity at a high dose. However, many adverse reactions are due to misuse or abuse of Chinese medicine.
Sources: en.wikipedia.org
== Nucleotide excision repair == As illustrated above, (+)-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) forms bulky covalent DNA adducts with guanines. Most of these adducts can be efficiently eliminated from DNA by the process of nucleotide excision repair. Those adducts that are not removed can cause errors during DNA replication leading to carcinogenic mutations.
== Revocation of nursing license == After the incident, the Tennessee Board of Nursing reviewed Vaught's case and initially rendered "a decision that [the] matter did not merit further action." However, In September 2019, the Tennessee Department of Health's Board of Nursing reversed their decision, charging Vaught with three infractions: unprofessional conduct, abandoning or neglecting a patient who required care, and failing to maintain an accurate patient record. In July 2021, the nursing board revoked Vaught's license and fined her $3,000. During her testimony, she took responsibility for the error, but also described procedural issues at the hospital. "Overriding was something we did as a part of our practice every day. You couldn't get a bag of fluids for a patient without using an override function." The Institute for Safe Medication Practices called the board decision "disturbing and unjust." It alleged that the decision reflected "significant outcome bias," "inability to differentiate between human error, at-risk behavior, and reckless behavior," "lack of a thorough investigation," and other shortcomings.
=== Post-independence (1946–1962) === The first elections after independence were the 1947 parliamentary election, with the People's Party winning a plurality in the Chamber of Deputies, but no absolute majority. In 1949, a series of military coups led to the dissolution of the Chamber of Deputies and constitutional suspensions. A Constituent Assembly elected in 1949 drafted the 1950 constitution, which strengthened parliamentary powers. Adib al-Shishakli's 1951 coup dissolved the Chamber of Deputies, and his 1953 election, with only 16% voter turnout, reconstituted the Chamber of Deputies as a 82-member legislative body under a presidential system. After his ouster in 1954, parliamentary rule was restored, with the People's Party and Ba'ath Party gaining influence. In 1958, the Chamber of Deputies was replaced by the UAR's National Assembly, where Syrians held one-third of the seats. Following Syria's withdrawal, the 1961 election restored parliamentary democracy.
During transport water needs to be maintained to a high quality, with regulated temperature, sufficient oxygen and minimal waste products. In some cases anaesthetics may be used in small doses to calm fish before transport. Aquaculture is sometimes part of an environmental rehabilitation program or as an aid in conserving endangered species.
Sources: en.wikipedia.org
=== MeSH D12.644.400 – neuropeptides === MeSH D12.644.400.070 – angiotensins MeSH D12.644.400.070.075 – angiotensin i MeSH D12.644.400.070.078 – angiotensin ii MeSH D12.644.400.070.080 – angiotensin iii MeSH D12.644.400.085 – bombesin MeSH D12.644.400.090 – bradykinin MeSH D12.644.400.095 – calcitonin MeSH D12.644.400.097 – calcitonin gene-related peptide MeSH D12.644.400.100 – carnosine MeSH D12.644.400.105 – cholecystokinin MeSH D12.644.400.120 – corticotropin MeSH D12.644.400.125 – corticotropin-releasing hormone MeSH D12.644.400.200 – delta sleep-inducing peptide MeSH D12.644.400.235 – fmrfamide MeSH D12.644.400.250 – galanin MeSH D12.644.400.275 – galanin-like peptide MeSH D12.644.400.300 – gastric inhibitory polypeptide MeSH D12.644.400.315 – gastrin-releasing peptide MeSH D12.644.400.320 – gastrins MeSH D12.644.400.340 – glucagon precursors MeSH D12.644.400.340.500 – glucagon MeSH D12.644.400.350 – gonadorelin MeSH D12.644.400.450 – motilin MeSH D12.644.400.460 – melanocyte-stimulating hormones MeSH D12.644.400.460.050 – alpha-msh MeSH D12.644.400.460.075 – beta-msh MeSH D12.644.400.460.115 – gamma-msh MeSH D12.644.400.465 – msh release-inhibiting hormone MeSH D12.644.400.470 – msh-releasing hormone MeSH D12.644.400.500 – neuropeptide y MeSH D12.644.400.525 – neurophysins MeSH D12.644.400.550 – neurotensin MeSH D12.644.400.575 – opioid peptides MeSH D12.644.400.575.180 – dynorphins MeSH D12.644.400.575.241 – endorphins MeSH D12.644.400.575.241.030 – alpha-endorphin MeSH D12.644.400.575.241.080 – beta-endorphin MeSH D12.644.400.575.241.360 – gamma-endorphin MeSH D12.644.400.575.281 – enkephalins MeSH D12.644.400.575.281.075 – enkephalin, ala(2)-mephe(4)-gly(5)- MeSH D12.644.400.575.281.231 – enkephalin, leucine MeSH D12.644.400.575.281.381 – enkephalin, methionine MeSH D12.644.400.575.281.600 – enkephalin, d-penicillamine (2,5)- MeSH D12.644.400.600 – pancreatic polypeptide MeSH D12.644.400.610 – peptide phi MeSH D12.644.400.625 – pituitary adenylate cyclase-activating polypeptide MeSH D12.644.400.640 – pituitary hormone release inhibiting hormones MeSH D12.644.400.645 – pituitary hormone-releasing hormones MeSH D12.644.400.680 – prolactin release-inhibiting hormone MeSH D12.644.400.700 – prolactin-releasing hormone MeSH D12.644.400.702 – thyrotropin-releasing hormone MeSH D12.644.400.705 – secretin MeSH D12.644.400.720 – somatostatin MeSH D12.644.400.740 – somatotropin-releasing hormone MeSH D12.644.400.800 – tachykinins MeSH D12.644.400.800.354 – eledoisin MeSH D12.644.400.800.475 – kassinin MeSH D12.644.400.800.500 – neurokinin a MeSH D12.644.400.800.550 – neurokinin b MeSH D12.644.400.800.625 – physalaemin MeSH D12.644.400.800.750 – substance p MeSH D12.644.400.875 – vasoactive intestinal peptide MeSH D12.644.400.900 – vasopressins MeSH D12.644.400.900.050 – argipressin MeSH D12.644.400.900.400 – lypressin MeSH D12.644.400.900.700 – oxytocin MeSH D12.644.400.900.900 – vasotocin
== Long-lasting erections == Antiandrogens can considerably relieve and prevent priapism (potentially painful penile erections that last more than four hours) via direct blockade of penile ARs. In accordance, bicalutamide, at low dosages (50 mg every other day or as little as once or twice weekly), has been found in a series of case reports to completely resolve recurrent priapism in men without producing significant side effects, and is used for this indication off-label. In the reported cases, libido, rigid erections, the potential for sexual intercourse, orgasm, and subjective ejaculatory volume have all remained intact or unchanged, and gynecomastia has not developed when bicalutamide is administered at a total dosage of 25 mg/day or less. Some gynecomastia and breast tenderness developed in one patient treated with 50 mg/day, but significantly improved upon the dosage being halved. The observed tolerability profile of bicalutamide in these subjects has been regarded as significantly more favorable than that of GnRH analogues and estrogens (which are also used in the treatment of this condition). However, although successful and well tolerated, very few cases have been reported. Despite the apparent efficacy of bicalutamide for priapism, a small clinical study found that bicalutamide monotherapy at a dosage of 50 mg/day had no effect on nocturnal erections in men with prostate cancer.
The Democratic National Committee (DNC) announced in May 2015 that there would be six debates. Critics alleged that the small number of debates and the schedule, with half of the debates on Saturday or Sunday nights, were part of the DNC's deliberate attempt to protect Clinton, who was perceived as the front-runner. In February 2016, both the Clinton and Sanders campaigns agreed in principle to holding four more debates for a total of ten. Clinton dropped out of the tenth debate, scheduled to take place just before the California primary, citing a need to devote her time to making direct contact with California voters and preparing for the general election. Sanders expressed disappointment that Clinton canceled the debate before what he believed would be "the largest and most important primary in the presidential nominating process."
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.